Arcadia Biosciences Inc (RKDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,407 | -4,610 | -16,134 | -6,577 | -3,740 |
| Depreciation Amortization | 795 | 328 | 7,271 | 1,870 | 1,171 |
| Accounts receivable | -1,333 | -1,398 | -40 | -47 | 259 |
| Other Working Capital | -1,525 | -872 | -4,263 | -3,357 | -963 |
| Other Operating Activity | 2,220 | 1,667 | -12,702 | -11,097 | -7,667 |
| Operating Cash Flow | $-8,250 | $-4,885 | $-25,868 | $-19,208 | $-10,940 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 795 | 747 | -988 | -917 | -713 |
| Net Acquisitions | N/A | N/A | -4,250 | -4,250 | -4,250 |
| Sale Of Investment | N/A | N/A | 21,846 | 21,845 | 21,845 |
| Investing Cash Flow | $795 | $747 | $16,608 | $16,678 | $16,882 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | -2,146 | -2,032 | -2,019 |
| Common Stock Issued | 4 | 4 | 25,208 | 25,208 | 25,174 |
| Other Financing Activity | 0 | 0 | -1,162 | -1,162 | -1,162 |
| Financing Cash Flow | $4 | $4 | $21,900 | $22,014 | $21,993 |
| Exchange Rate Effect | N/A | N/A | 2 | -1 | -1 |
| Beginning Cash Position | 28,685 | 28,685 | 16,043 | 16,043 | 16,043 |
| End Cash Position | 21,234 | 24,551 | 28,685 | 35,526 | 43,977 |
| Net Cash Flow | $-7,451 | $-4,134 | $12,642 | $19,483 | $27,934 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,250 | -4,885 | -25,868 | -19,208 | -10,940 |
| Capital Expenditure | -46 | -40 | -1,007 | -919 | -713 |
| Free Cash Flow | -8,296 | -4,925 | -26,875 | -20,127 | -11,653 |